Certest Showcases Range of Rapid Tests and Real Time PCR Detection Kits at MEDICA 2021
|
By LabMedica International staff writers Posted on 15 Nov 2021 |

CerTest Biotec (Zaragoza, Spain) showcased its range of rapid tests and real time PCR detection kits at the MEDICA 2021 trade fair held in Düsseldorf, Germany from 15-18th November. MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals.
CerTest highlighted different products for infectious diseases, tumor and inflammation markers detection. The company also presented its range of enzymes for molecular biology and qPCR. CerTest highlighted its range of monoclonal antibodies with high sensitivity and specificity by using highly stable and pure immunogens and an in-house improved screening; liquid recombinant proteins with high purity and stability, through a process of cloning, expression, multi-step purification and buffer optimization; native antigens -inactivated- comprising a wide variety of bacteria and viruses; and molecular biology enzymes with high specific activity and high stability, with and w/o glycerol that are suitable for qPCR and RT-qPCR.
CerTest also presents its rapid test diagnostic products for detecting the presence of antigens with the immunochromatographic lateral flow technique. These products included rapid diagnostic tests for gastrointestinal, respiratory infectious diseases, and the detection of inflammatory or tumor markers in the GI tract. The company demonstrated why its rapid tests are easy to use, along with its robust and stable diagnostic devices that are designed to provide the best performance in the simplest way and at the lowest associated operational costs. Also on display was CerTest’s Turbilatex product line including turbidimetric assays based on the agglutination reaction between antibody-coated latex particles and the antigen in solution, as well as reagents that permit a high-sensitivity detection method to be obtained. The intended use for Turbilatex products is to detect and quantify the antigen present in human stool samples.
Additionally, CerTest showcased its VIASURE Real Time PCR Detection Kits that are designed for the diagnosis of infectious diseases caused by different pathogens in human samples. This product range is based on 5’ nuclease chemistry. This technology utilizes two primers and a hydrolysis probe and exploits the exonuclease activity of Taq DNA polymerase. During the amplification, the increase in the fluorescent signal is proportional to the quantity of target sequence present in the sample and could be measured on a wide range of Real Time PCR platforms. VIASURE Real Time PCR Detection Kit contains in each well all the necessary components for Real Time PCR assay in a stabilized format, which allows the shipment at room temperature.
Related Links:
CerTest Biotec
Latest Medica 2021 News
- MEDICA 2021 + COMPAMED 2021 Far Exceed Expectations and Achieve Extremely Successful Results
- POC System that Requires Single DNA Molecule for Rapid Detection of Multidrug-Resistant Pathogens Unveiled at MEDICA 2021
- Icomes Lab Demonstrates World's Smallest and Lightest Electronic Pipette for PCR Testing at MEDICA 2021
- Bosch Exhibits Vivalytic All-in-One Analyzer for PCR Rapid Tests at MEDICA 2021
- Co-Diagnostics Introduces Its Revolutionary Coprimer Technology at MEDICA 2021
- MGI Tech Showcases World-First High-Throughput Automated Sample Transfer Processing System at MEDICA 2021
- Edan Debuts Next-Gen Blood Gas & Chemistry Analyzer and Patient Monitor at MEDICA 2021
- EKF Diagnostics Showcases STAT-Site WB β-ketone and Glucose Handheld Analyzer Live & in Person at MEDICA 2021
- Boditech Launches New Automated Immunoassay Analyzer with Blood Collection Tube at MEDICA 2021
- Molgen Presents Diagnostics Chemistry, Flows and Systems at MEDICA 2021
- Randox Showcases Extensive Range of Revolutionary Diagnostic Analyzers at MEDICA 2021
- Molbio Exhibits Its Novel POC Molecular Platform and Truenat Range of Tests at MEDICA 2021
- Greiner Bio-One Exhibits Its New Generation of Sapphire Pipette Tips at MEDICA 2021
- LumiraDx Presents Its Innovative, Next Generation Point of Care Diagnostics Platform at MEDICA 2021
- Medix Biochemica Celebrates Launch of New Molecular Diagnostic Reagents Division at MEDICA 2021
- Fujirebio Highlights Its Innovative IVD Testing Solutions for Today and Tomorrow at MEDICA 2021
Channels
Clinical Chemistry
view channel
Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
Accurate diabetes detection is essential because early identification guides timely management, yet test performance can vary in people with hemoglobin variants such as sickle cell trait.... Read more
Blood Protein Panel Predicts Timing of ALS Symptom Onset
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which clinical signs often emerge only after substantial motor neuron injury has already occurred, complicating timely intervention.... Read moreMolecular Diagnostics
view channel
AI Tool Improves Long-Read Detection of Cancer Mutations
Accurate identification of somatic mutations remains difficult, particularly in structurally complex genomic regions. Short-read sequencing pipelines can miss clinically relevant variants, limiting research... Read more
FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
Vaginitis is a common reason for clinical visits, with bacterial vaginosis and Candida vaginitis among the leading causes. Overlapping symptoms and reliance on microscopy, pH testing, and clinical observation... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read morePathology
view channel
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelLumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more









